CaroGen reports that the United States Patent and Trademark Office has issued CaroGen’s first composition of matter patent for its Artificial Virus (AV) for Infectious Diseases (ID) and Immuno/Oncology (IO) platform dubbed “AVIDIO”.
CaroGen’s CEO and Co-founder, Bijan Almassian, PhD, stated, “Receiving such a broad patent claims by the USPTO is great welcome news as we are advancing our first AVIDIO-based immunotherapy CARG-201 for potential cure of patients chronically infected with hepatitis B virus (HBV) into human clinical trials and investigating AVIDIO based immunotherapies for co-lon and other cancer targets in collaboration with academic institutes.” more